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Abstract. The aim of the present study was to report the genetic 
and immunohistochemical profile of a rare case of lacrimal 
gland oncocytoma. A 20-year-old male underwent magnetic 
resonance imaging (MRI) due to viral encephalitis. Notably, 
the MRI revealed a multicystic tumor in the left lacrimal 
gland. A lateral orbitotomy was performed and the tumor 
was completely excised. Four months following surgery, the 
patient was free of symptoms. Histopathologically, the tumor 
was composed of large, eosinophilic and polyhedral cells 
with small round nuclei. The tumor cells stained strongly for 
antimitochondrial antibody MU213-UC, cytokeratin (CK) 5/6, 
CK 7, CK 17, CK 8/18 and CK 19. The final diagnosis was 
an oncocytoma of the lacrimal gland without any signs of 
malignancy. Array-based comparative genomic hybridisation 
demonstrated a gain of one copy of chromosome 8 and loss 
of one copy of chromosome 22 as the sole genomic imbal-
ances. These chromosomal alterations have not previously 
been identified in oncocytoma and may be specific to lacrimal 
gland oncocytoma. Sequencing of the mitochondrial genome 
demonstrated multiple alterations of the NADH-ubiquinone 
oxidoreductase chain 5 (ND5) gene involved in mitochondrial 
oxidative phosphorylation. This may support the notion of 
a common genetic background of oncocytic lesions in the 
lacrimal gland and other anatomical sites.
Introduction
Oncocytoma is a rare benign neoplasm that may arise in the 
glandular epithelium of salivary glands, thyroid, parathyroid, 
kidney, adrenal cortex, and in the ocular region (1-3). The 
oncocytic cells (oncocytes, from the Greek onkoustai, meaning 
to swell) have a swollen appearance, and are characterised by 
a large number of morphologically abnormal and possibly 
dysfunctional mitochondria (2,4). Ocular adnexal oncocytoma 
is rare and occurs most frequently in the caruncle, although 
lesions have also been identified on the eyelid margin, the 
conjunctiva, in the lacrimal sac, and in the lacrimal gland (1). 
In 1959, the first case of a lacrimal gland oncocytoma was 
reported by Beskid and Zarzycka (5), since then 12 additional 
cases have been reported (Table I) (5-16). The molecular patho-
genesis of lacrimal gland oncocytoma, and the mechanisms 
leading to the combined intracellular mitochondrial prolif-
eration and the proliferation of the oncocyte itself remains 
unclear (2). It has been suggested that mitochondria may be 
involved in oncocytoma pathogenesis, and several studies 
have identified multiple sequence variants in mitochondrial 
DNA (mtDNA), particularly in genes involved in the cellular 
respiration complex I (2,4,16-18). In the present study, a case 
of lacrimal gland oncocytoma was described, and a detailed 
immunohistochemical profile was presented along with a 
genetic profile of the tumor based on high‑resolution array 
comparative genomic hybridisation (aCGH) of nuclear DNA 
and next-generation sequencing of the mitochondrial genome.
Materials and methods
Clinical history. A 20-year-old male was hospitalised from 
January 3rd to January 21st 2015 (Rigshospitalet, Copenhagen 
University Hospital, Denmark) due to encephalitic symp-
toms. Unexpectedly, magnetic resonance imaging revealed 
an ~2x2x2 cm multicystic tumor in the lacrimal gland of the 
left orbit along with a 5-mm protrusion of the left eye causing 
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pronounced asymmetry of the orbital region (Fig. 1A-C). 
Computer tomography confirmed that the orbital roof was 
intact without tumor infiltration. The orbital roof was remod-
elled consistent with a slow growing benign tumor. The tumor 
expanded posteriorly in the orbit due to cystic areas in the 
tumor. The patient received treatment for encephalitis, and 
was subsequently referred for ophthalmic evaluation of the 
lacrimal gland mass. No visual symptoms, pain, or cosmetic 
changes had been noticed by the patient. Images revealed 
that the patient had symmetry of the orbital region two years 
previously. On examination prior to operation, visual acuity 
measured with the Snellen chart was normal (6/6 s.c.) in the 
right eye and reduced (6/30 s.c.) in the left eye. The patient was 
not amblyopic and the reduced visual acuity in the left eye was 
explained by the refraction error caused by the tumor mass 
deforming the eyeball (Fig. 1B). Proptosis (Hertel 18/23-95) 
of the left eye was present, and the eye was displaced 2 mm 
medially and downwards. When examined the patient reported 
vertical diplopia. The intraocular pressure was 12 mmHg in the 
right eye and 15 mmHg in the left eye measured with Goldman 
applanation tonometry. Palpation of the lacrimal fossa 
revealed a smooth mass. The patient had decreased supero-
lateral movement of the left eye due to the space-occupying 
lesion. Slit-lamp microscopy, including ophthalmoscopy was 
normal. Pupillary reflexes, colour vision and visual fields were 
normal. A lateral orbitotomy was performed, and the tumor 
was completely excised. Four months following surgery, the 
visual acuity was 6/6 s.c. in both eyes and the patient was free 
of any symptoms.
Histopathology and immunohistochemistry. Formalin‑fixed 
paraffin‑embedded (FFPE) tissue from the resected orbital 
tumor was sectioned and stained with haematoxylin and eosin, 
Alcian blue, periodic acid-Schiff (PAS), and phosphotungstic 
acid-haematoxylin (PTAH) according to standard protocols 
as previously described (1). Immunohistochemical stainings 
of 4 µm sections were performed using the following anti-
bodies: Mitochondrial antibody MU213-UC (monoclonal, 
clone no. 113-1; cat no. MU2130506; mouse anti-human; 
1:10; BioGenex Laboratories, Inc., San Ramon, CA, USA), 
Ki-67 (monoclonal, clone MIB-1, cat no. M724001, mouse 
anti-human; 1:100), S-100 (polyclonal, cat no. Z0311, rabbit 
anti-human; 1:4,000), cytokeratin (CK) 5/6 (monoclonal, clone 
D5/16 B4, cat no. M723701, mouse anti-human; 1:20), CK 7 
(monoclonal, clone OV-TL 12/30, cat no. M701801, mouse 
anti-human; 1:1,000), CK 8/18 (monoclonal, clone EP17/EP30, 
cat no. M365201-2, rabbit anti-human; 1:50) (all from Dako; 
Agilent Technologies, Inc., Santa Clara, CA, USA), CK 14 
(monoclonal, clone LL002, cat no. NCL-LL002; mouse 
anti-human; 1:40; Novocastra; Leica Biosystems Newcastle, 
Newcastle, UK), CK 17 (monoclonal, clone E3, cat no. M 7046; 
mouse anti-human; 1:20), CK 19 (monoclonal, clone RCK 108, 
cat no. M0888; mouse anti-human; 1:100), CK 20 (monoclonal, 
clone Ks 20.8, cat no. M 7019; mouse anti-human), cluster of 
differentiation (CD)117 (polyclonal, cat no. A450229, rabbit 
anti-human; 1:100), smooth muscle actin (SMA; monoclonal, 
clone 1A4, cat no. M0851, mouse anti-human, 1:100), carci-
noembryonic antigen (CEA; monoclonal, clone IL-7, cat 
no. M7072; mouse anti-human; 1:50), and epithelial membrane 
antigen (EMA; monoclonal, clone E29, cat no. M0613; mouse 
antihuman; 1:1,000) (all from Dako; Agilent Technologies, 
Inc.). The blocking reagent was peroxidase (37˚C, 10 min incu-
bation). Incubation with primary antibody occurred at 37˚C 
for 32 min. Secondary antibodies were used as previously 
described (1). Immunohistochemistry was performed using 
the Ventana BenchMark ULTRA platform (Ventana Medical 
Systems, Inc., Tucson, AZ, USA). The MU213-UC staining was 
performed using a biotin-free method (EnVision Flex+; Dako; 
Agilent Technologies, Inc.) to avoid a false-positive reaction 
caused by endogenous biotin in the mitochondrial-rich tissue as 
previously described (1). Appropriate controls were included. 
All slides were assessed using an Axioplan 2 Imaging light 
microscope (Zeiss, Oberkochen, Germany). The investigation 
adheres to the tenets of the Declaration of Helsinki (19) and 
the patient provided informed consent.
aCGH. Genomic DNA was isolated from FFPE tumor tissue 
using the QIAamp® DNA FFPE Tissue kit (Qiagen GmbH, 
Figure 1. (A) A 20-year-old male presented with left-sided proptosis as the 
only finding (arrow), the bilateral upper lid retraction was habitual. (B) Axial 
and (C) sagittal magnetic resonance imaging scans demonstrating a cystic 
lacrimal gland tumor measuring 2x2x2 cm in the left orbit (arrowheads). The 
tumor was located far posteriorly for a lacrimal gland tumor. This was due 
to a cystic tumor area expanding posteriorly. (D) The tumor cells were large 
and eosinophilic with abundant granular cytoplasm (haematoxylin and eosin; 
bar, 50 µm). Inset presents normal lacrimal gland tissue in the periphery 
of the specimen. (E) The tumor cells contained abundant mitochondria 
(anti-MU213-UC staining, red; bar, 50 µm). (F) The tumor cells stained 
positively for EMA (bar, 150 µm). (G) The tumor cells stained positively for 
S-100 (bar, 100 µm). (H) The tumor cells stained positively for CK8 (bar, 
50 µm).
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Hilden, Germany) according to the manufacturer's protocol. 
aCGH analysis was performed using the 180K oligonucleotide 
CGH microarray (G4449A; Agilent Technologies Inc.) as previ-
ously described (20,21). The slide was scanned on an Agilent 
High-Resolution C Microarray scanner, followed by data 
extraction and normalisation using Feature Extraction v10.7.1 
with linear normalisation (protocol CGH_107_Sep09) (both 
from Agilent Technologies Inc.). Data analysis was performed 
using Nexus Copy Number software® Discovery Edition v8.0 
(BioDiscovery Inc., El Segundo, CA, USA) as previously 
described (21). The FASST2 segmentation algorithm was used 
to define non‑random regions of CNAs across the genome 
with a significance threshold set to P=1.0x10-6. The log2 ratio 
thresholds for aberration calls were set to 1.5 for high copy 
number gain/amplification, 0.2 for gain, ‑0.2 for loss, and ‑1.5 
for homozygous deletion. Each aberration was checked manu-
ally to confirm the accuracy of the call. Sex chromosomes and 
regions partially or completely covered by a previously reported 
copy number variation (Database of Genomic Variants; 
http://dgvbeta.tcag.ca/dgv/app/news?ref=NCBI37/hg19) were 
excluded from the analysis.
Mitochondrial DNA sequencing. Whole mitochondrial 
genome sequencing was performed on the Ion PGM™ system 
with the Precision ID mtDNA Whole Genome Panel (both 
Thermo Fisher Scientific, Inc., Waltham, MA, USA). Library 
Table II. Mitochondrial DNA sequencing. 
SNP MT-locus Amino acid change Frequency GenBank frequency (%) Polyphen-2.2 (score)
A73G D-loop Non-coding 100.0 23631 (73.71) 
C150T D-loop Non-coding 98.3 3787 (11.81) 
G185A D-loop Non-coding 100.0 1274 (3.97) 
A263G D-loop Non-coding 100.0 29979 (93.51) 
323_324insC D-loop Non-coding 100.0 0 (0.00) 
A750G RNR1 (12s-RNA) rRNA 100.0 31410 (97.98) 
A1438G RNR1 (12s-RNA) rRNA 100.0 30179 (94.14) 
C1721T RNR2 (16s-RNA) rRNA 100.0 225 (0.70) 
A2706G RNR2 (16s-RNA) rRNA 100.0 24784 (77.31) 
T3197C RNR2 (16s-RNA) rRNA 100.0 1350 (4.21) 
A3243Ga L(UUA/G)/TER tRNA 94.5 8 (0.02) 
A4769G ND2 Synonymous 100.0 31182 (97.26) 
A4958Ga ND2 Synonymous 100.0 115 (0.36) 
C7028T CO1 Synonymous 100.0 25290 (78.89) 
A7768G CO2 Synonymous 100.0 592 (1.85) 
A8860G ATP6 Non-syn:Thr→Ala 100.0 31527 (98.34) Benign (0)
G9477A CO3 Non-syn:Val→Ile 100.0 1344 (4.19) Benign (0)
A9670Ga CO3 Non-syn: Asn→Ser 100.0 28 (0.09) Benign (0.01)
A11467G ND4 Synonymous 100.0 4213 (13.14) 
A11653G ND4 Synonymous 100.0 194 (0.61) 
G11719A ND4 Synonymous 100.0 24160 (75.36) 
A12308G L(CUN) tRNA 97.5 4193 (13.08) 
G12372A ND5 Synonymous 100.0 4519 (14.10) 
A12530Ga ND5 Non-syn:Asn→Ser 100.0 20 (0.06) Benign (0.06)
A12634Ga ND5 Non-syn:Ile→Val 100.0 91 (0.28) Probably damaging (1)
T13617C ND5 Synonymous 100.0 1315 (4.10) 
A13630Ga ND5 Non-syn:Thr→Ala 100.0 62 (0.19) Benign (0.05)
A13637G ND5 Non-syn:Gln→Arg 100.0 287 (0.90) Benign (0.1)
T14182C ND6 Synonymous 100.0 843 (2.63) 
C14766T CYTB Non-syn:Thr→Ile 100.0 24091 (75.15) Benign (0.01)
A15326G CYTB Non-syn:Thr→Ala 100.0 31512 (98.29) Benign (0.02)
C16270T D-loop Non-coding 100.0 8147 (25.41) 
T16519C D-loop Non-coding 100.0 1694 (5.28) 
aSNP identified in <0.5% of known mutations in the GenBank®. One insertion and multiple SNPs were identified in the D‑loop. Four 
non‑synonymous (non‑syn) SNPs were identified in the ND5 region, which is a part of the respiratory complex I. The Polyphen‑2 tool predicts 
the potential damage provided by an SNP. MT, mitochondrial; SNP, Single nucleotide polymorphism; ND, NADH-ubiquinone oxidoreductase 
chain; D-loop, displacement-loop.
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preparation was performed according to the Ion AmpliSeq Kit 
for Chef DL8 with minor modifications. After PCR of panel 
pool 1 and pool 2, the products were pooled for library prepa-
ration. Ion PGM IC 200 kit was used as the template kit for the 
IonChef (both from Thermo Fisher Scientific, Inc.). Sequencing 
was carried out using Ion PGM IC 200 Sequencing kit (TRS) 
with the Ion 318™ Chip v2 (Thermo Fisher Scientific, Inc.). 
Variant calling was carried out using the Torrent Variant 
Caller v4.6 of the Torrent Suite™ software (Thermo Fisher 
Scientific, Inc.). PrecisionID_mtDNA_rCRS.fasta was used as 
the reference genome with PrecisionID_mtDNA_WG_targets.
bed as panel the BED (Thermo Fisher Scientific, Inc.), and 
PrecisionID_mtDNA_TVCv4.6_AnalysisParams.json as the 
analysis parameter settings (Thermo Fisher Scientific, Inc.).
Variants were discarded if the coverage was below x25 
and the minimum heteroplasmy threshold level was set to 
10% of the coverage. Data was analysed using the MitoMaster 
tool (22) and the MitImpact version 2.7 (23). The Polyphen-2 
tool was used to predict harmful single nucleotide polymor-
phisms (SNP) with a frequency <0.5% in the GenBank® (24).
Results
Histopathology. Macroscopically, the tumor measured 
25x22x17 mm. The tumor was non-encapsulated. The colour 
was deep red with blue cystic areas. Microscopic examination 
revealed large, cylindrical, eosinophilic and basal oriented 
tumor cells (Fig. 1D). It was not possible to identify normal 
ducts between the tumor cells, but normal ducts were located 
in the periphery of the specimen, possibly consistent with 
lacrimal gland oncocytoma, arising from a glandular duct. 
PAS staining was positive in a small fraction of the tumor 
cells and in the cystic content. Staining with Alcian blue was 
negative. PTAH was positive in the tumor cells. An extended 
immunoprofile included strong reactivity for CK 5/6, CK 7, 
CK 8/18, CK 17, CK 19, S-100, and EMA. CD117 was slightly 
positive and CK 14 was positive in ~30% of the basal-type cells. 
The cytokeratin profile was similar to that of normal lacrimal 
gland tissue and other ocular adnexal oncocytomas (1). The 
tumor cells stained positively for the mitochondrial antigen, 
MU213-UC (Fig. 1E). Staining with anti-Ki67 revealed 
positivity in <1% of the tumor cell nuclei, indicating a low 
proliferative index. The tumor cells were negative for CK 20, 
CEA and SMA.
Genetic profile. Genome-wide aCGH analysis revealed a 
genomic profile characterised by gain of one copy of chromo-
some 8 and loss of one copy of chromosome 22 as the sole 
imbalances (Fig. 2). There was no evidence of gene amplifica-
tions or homozygous deletions.
mtDNA sequencing. Sequencing of the mtDNA revealed 33 
sequence variants (Table II). Five SNPs were recognised in 
<0.5% of the samples in the GenBank®. Four non-synonymous 
SNPs were identified in the NADH‑ubiquinone oxidoreduc-
tase chain 5 (ND5) gene, which is part of the respiratory 
complex I. Additionally, an insertion at site 524 was identi-
fied in the displacement‑loop (D‑loop). One non‑synonymous 
SNP (A12634G) possibly had a damaging effect. Additionally, 
SNPs were also identified in the ND2, ND4 and ND6 genes of 
the respiratory complex I. However, these SNPs were synony-
mous. Two non-synonymous SNPs (A9670G and G9477A) 
were identified in the cytochrome oxidase subunit III gene, 
which is part of the respiratory complex IV. None of the 
synonymous SNPs were involved in splice sites. No transver-
sions were identified.
Discussion
The present study described the immunohistochemical and 
genetic profile of a rare case of lacrimal gland oncocytoma 
in a 20-year-old male. This is the 13th case of lacrimal gland 
Figure 2. (A) Schematic, partial karyogram demonstrating a gain of one copy of chromosome 8 (vertical blue line) and loss of one copy of chromosome 22 
(vertical red line) as the sole genomic imbalances in the lacrimal oncocytoma. (B) Sequencing of the mitochondrial DNA revealed multiple non-synonymous 
single nucleotide polymorphisms in genes (ND2, ND5, and ND6) involved in the respiratory complex I. Several synonymous single nucleotide polymorphisms 
were identified in the entire mitochondrial genome. One possibly damaging mutation was identified  in the ND5 gene (arrow). ND, NADH-ubiquinone 
oxidoreductase chain.
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oncocytoma in the literature. Men and women are equally 
affected, with a median age at the time of diagnosis of 57 years 
(range, 1-83 years; Table I). The symptoms of lacrimal gland 
oncocytoma range from mild lid swelling without pain to 
proptosis with severe pain (10,13). The majority of lacrimal 
gland oncocytomas were surgically removed through a lateral 
orbitotomy or more rarely through a fronto-orbitozygomatic 
craniotomy (13). All patients with lacrimal gland oncocytoma 
were alive at the time of the last follow-up (3-42 months) (8). 
Malignant transformation or recurrence of lacrimal gland 
oncocytoma following complete surgical excision has not been 
reported. Hence, a possible association between oncocytoma 
and the exceedingly rare oncocytic carcinoma is unclear.
Little is known about the genetic changes leading to onco-
cytoma formation. In the present case, a gain of one copy of 
chromosome 8 and loss of one copy of chromosome 22 were 
identified as the sole genomic imbalances. To the best of our 
knowledge, none of these alterations have previously been 
described in oncocytoma of any sites. The significance of the 
findings of the current study is unclear. However, it appears 
that genomic instabilities are typical for oncotoma that occurs 
in males (16). Exome sequencing of renal oncocytoma has 
identified two main types. A diploid oncocytoma that has no 
sex predilection and another type that has a male predilec-
tion, and is a hypodiploid oncocytoma with complete loss 
of chromosome 1, 14, 21, X, or Y (16). Other chromosomal 
aberrations have been described in oncocytic lesions of the 
thyroid, including losses and gains of both arms of chromo-
somes 1, 2, 5, 7, 12, 17, 19, 20 and 22 (4). However, only gains 
involving chromosome 22 have been reported, contrasting 
with the loss of chromosome 22 in the present case (4). The 
trisomy 8 in the current case is similarly unprecedented, but 
trisomy 7 has been demonstrated in a case of salivary gland 
oncocytoma (25). There may be a site specific difference in 
the alterations identified in oncocytoma, as the frequent chro-
mosomal aberrations observed in renal, thyroid and salivary 
oncocytoma are different, and diffuse (16-18,25). This supports 
the idea that the results of the present study may be specific to 
lacrimal gland oncocytoma, since these changes have not been 
observed elsewhere. Deletions, SNPs and rearrangements 
have been described in mtDNA in oncocytoma of the thyroid, 
kidney, salivary glands, and adrenal cortex (2). In line with 
the apparent association between the oncocytic phenotype and 
mtDNA gene aberrations, specifically in genes involved in 
complex I function, several sequence variants in the mitochon-
drial genome of the present case were identified. The majority 
of these were transitions, but one insertion was identified at 
mtDNA position 524. Insertions in the D-loop have previously 
been reported in thyroid adenoma (18). In addition, six SNPs 
were identified in <0.5% of the 32,000 mitochondrial genomes 
registered in the GenBank®. Notably, two synonymous and four 
non-synonymous SNPs were detected in the ND5 gene, which 
is a part of the respiratory complex I. Of note, the consequence 
of one SNP in ND5 was termed ‘probably damaging’ with 
the PolyPhen-2 tool for functional annotation of genetic vari-
ants, thereby supporting a fundamental pathogenic similarity 
between lacrimal gland oncocytoma and oncocytic lesions in 
other anatomical sites. Overall, these mtDNA variants may 
potentially impair cell respiration, and be responsible for the 
slow-proliferating nature of the tumor.
It is thought that mutations in the mitochondrial genes 
encoding proteins involved in oxidative phosphorylation may 
result in compensatory mitochondrial proliferation, while 
mutations in nuclear genes encoding oxidative phosphoryla-
tion proteins are less frequently involved (2). The cause of 
mitochondrial proliferation and the possible association with 
proliferation of the oncocyte itself remains unclear.
In conclusion, a gain of one copy of chromosome 8 and 
loss of one copy of chromosome 22 were identified in a rare 
case of lacrimal gland oncocytoma. In addition to these gross 
alterations of nuclear DNA, a peculiar involvement of appar-
ently damaging mitochondrial point mutations resulting in 
impairment of respiratory function was reported, similar to 
what has previously been reported in oncocytoma from other 
anatomical sites, suggesting a potential involvement of mito-
chondria in oncocytoma pathogenesis.
Oncocytoma of the ocular adnexa is more common in the 
lacrimal caruncle (1). It would be of interest in future studies 
to compare CGH and mitochondrial sequencing results of a 
selection of these lesions to the current case to evaluate the 
molecular changes in ocular adnexal oncocytoma.
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